ZBH.SW down 4.26% pre-market on SIX: Zimmer Biomet faces near-term support test

ZBH.SW stock opened pre-market on the SIX at CHF 67.50, down 4.26% from the prior close. The move places Zimmer Biomet Holdings, Inc. (ZBH.SW) at its intraday low and at the year low of CHF 67.50. Volume is light at 110 shares but relative volume is high at 36.67, signalling concentrated orders before the session. Traders and analysts will watch earnings guidance and sector flows in Healthcare as immediate catalysts.

Pre-market price and drivers: ZBH.SW stock

Zimmer Biomet (ZBH.SW) is trading on the SIX in Switzerland at CHF 67.50 after a CHF 3.00 drop from yesterday. The one-day decline of -4.26% follows weak momentum and the stock sitting below its 50-day average of CHF 78.58 and 200-day average of CHF 87.90. News catalysts are light, so market structure and flows in the Healthcare sector are likely amplifying the move.

Earnings, fundamentals and growth

Trailing EPS stands at CHF 2.70 with a PE ratio of 25.00 based on the current price. Zimmer Biomet reports market cap of CHF 13,206,510,270.00 and 195,652,004.00 shares outstanding. Revenue-per-share is CHF 41.76 and free cash flow per share is CHF 8.02, but net income declined year-on-year and EPS growth is negative, which helps explain the cautious investor stance.

Technicals and trading metrics

Technical indicators show short-term stress: RSI at 75.66 reads as overbought, while ADX at 84.17 indicates a strong trend. Price sits below both the 50-day and 200-day averages, signalling a longer-term downtrend. Pre-market volume is 110 versus an average volume of 3, giving a relative volume of 36.67 that may exaggerate intraday moves.

Meyka Grade and forecast analysis

Meyka AI rates ZBH.SW with a score out of 100: 77.50 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of CHF 59.16 and a yearly price of CHF 58.07, compared with the current CHF 67.50, showing model-based downside. Forecasts are model-based projections and not guarantees.

Valuation, price targets and analyst context

Key valuation ratios include a PB ratio of 1.33 and EV/EBITDA of 11.56, which sit below some sector peers. The Graham number is CHF 72.01, providing a conservative fair-value reference. Short-term technical target: CHF 72.00. Conservative 12-month model target: CHF 58.07 (Meyka yearly), implying downside of -13.98% from today.

Risks, sector context and trading strategy

Sector flows in Healthcare have softened; the sector average PE is 29.45, higher than ZBH.SW’s PE of 25.00, suggesting relatively cheaper valuation. Key risks include slower procedure volume, inventory inefficiencies, and higher leverage. Traders should watch support at CHF 67.50 and resistance at CHF 78.58, and consider position sizing due to the stock’s volatility.

Final Thoughts

ZBH.SW stock opened pre-market on the SIX at CHF 67.50, down 4.26%, and now trades at its year low. Fundamentals show mixed signals: EPS CHF 2.70 and free cash flow per share CHF 8.02 support long-term value, but recent net income declines and weaker margins pressure sentiment. Meyka AI’s forecast model projects a yearly price of CHF 58.07, an implied downside of -13.98% versus the current price. Our short-term technical target is CHF 72.00, with a conservative range to CHF 58.07 for 12 months. Meyka AI’s proprietary grade (B+, score 77.50) blends sector and benchmark comparisons with growth and metrics, and flags both opportunity and risk. For traders, the immediate test is support at CHF 67.50; for investors, compare the company’s PE of 25.00 and PB of 1.33 to peers and your risk tolerance. These views use data-driven signals from Meyka AI, and forecasts are model-based projections that are not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.